BIOMAT Database Logo BIOMAT Database Logo

Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer. 2021

R K Ismail, and J van Breeschoten, and M W J M Wouters, and M van Dartel, and S van der Flier, and A K L Reyners, and P de Graeff, and A M G Pasmooij, and A de Boer, and K E Broekman, and D L Hilarius
Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, Leiden, 2333AA, the Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, the Netherlands. Electronic address: r.ismail@dica.nl.

BACKGROUND This study aimed to provide insights into the real-world use of palbociclib, dose reductions, and drug effectiveness in (older) patients with advanced breast cancer (BC). METHODS Patients with advanced BC treated with palbociclib from 2017 to 2020 were included. The Kaplan-Meier method was used to calculate time to next treatment (TTNT) and overall survival (OS) for patients with or without dose reductions. These clinical outcomes were also compared in subgroup analyses for older patients (≥70 years) and younger patients (<70 years) and for patients discontinuing palbociclib early (<4 administrations). RESULTS A total of 598 patients with advanced BC were included, with a median age of 64 years. Palbociclib dose reductions occurred in 33% of all patients. Early discontinuation of palbociclib without dose reductions occurred in 23% of the patients. Patients who required a palbociclib dose reduction were older (median age 67 years vs. 63 years). Patients with dose reductions had a significantly higher TTNT of 16.9 vs. 11.4 months (p < 0.001) and median OS of 29.7 vs. 21.9 months (p = 0.003) compared to patients without dose reductions. The TTNT in older patients was significantly longer (16.9 vs. 11.6 months, p = 0.013) than younger patients, but OS was similar (20.7 vs. 26.7 months, p = 0.051). CONCLUSIONS Palbociclib dose reductions occurred in real-world practice similarly to the PALOMA-3 trial. Patients with dose reductions had no poorer outcomes compared to patients not requiring a dose reduction. Older patients treated with palbociclib had more frequent dose reductions, but this did not appear to affect OS.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000084862 Drug Tapering Gradual discontinuation or reduction of a therapeutic dose of a particular drug over a period of time. Dose Reduction,Dose Tapering,Dose Reductions,Dose Taperings,Reduction, Dose,Reductions, Dose,Tapering, Dose,Tapering, Drug,Taperings, Dose
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D018719 Receptor, ErbB-2 A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member. HER-2 Proto-Oncogene Protein,Proto-Oncogene Protein HER-2,Proto-Oncogene Protein p185(neu),c-erbB-2 Protein,erbB-2 Proto-Oncogene Protein,erbB-2 Receptor Protein-Tyrosine Kinase,neu Proto-Oncogene Protein,Antigens, CD340,CD340 Antigen,Erb-b2 Receptor Tyrosine Kinases,Metastatic Lymph Node Gene 19 Protein,Neu Receptor,Oncogene Protein HER-2,Proto-Oncogene Proteins c-erbB-2,Proto-oncogene Protein Neu,Receptor, Neu,Receptors, erbB-2,Tyrosine Kinase-type Cell Surface Receptor HER2,p185(c-neu),p185erbB2 Protein,CD340 Antigens,Erb b2 Receptor Tyrosine Kinases,ErbB-2 Receptor,HER 2 Proto Oncogene Protein,Oncogene Protein HER 2,Proto Oncogene Protein HER 2,Proto Oncogene Proteins c erbB 2,Proto-Oncogene Protein, HER-2,Proto-Oncogene Protein, erbB-2,Proto-Oncogene Protein, neu,Tyrosine Kinase type Cell Surface Receptor HER2,c erbB 2 Protein,erbB 2 Proto Oncogene Protein,erbB 2 Receptor Protein Tyrosine Kinase,erbB-2 Receptors,neu Proto Oncogene Protein

Related Publications

R K Ismail, and J van Breeschoten, and M W J M Wouters, and M van Dartel, and S van der Flier, and A K L Reyners, and P de Graeff, and A M G Pasmooij, and A de Boer, and K E Broekman, and D L Hilarius
Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?
April 2022, Breast (Edinburgh, Scotland),
R K Ismail, and J van Breeschoten, and M W J M Wouters, and M van Dartel, and S van der Flier, and A K L Reyners, and P de Graeff, and A M G Pasmooij, and A de Boer, and K E Broekman, and D L Hilarius
Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer.
March 2018, Anti-cancer drugs,
R K Ismail, and J van Breeschoten, and M W J M Wouters, and M van Dartel, and S van der Flier, and A K L Reyners, and P de Graeff, and A M G Pasmooij, and A de Boer, and K E Broekman, and D L Hilarius
Impact of early dose intensity reduction of Palbociclib on clinical outcomes in patients with hormone-receptor-positive metastatic breast cancer.
September 2020, Breast cancer research and treatment,
R K Ismail, and J van Breeschoten, and M W J M Wouters, and M van Dartel, and S van der Flier, and A K L Reyners, and P de Graeff, and A M G Pasmooij, and A de Boer, and K E Broekman, and D L Hilarius
Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.
September 2019, Breast cancer (Tokyo, Japan),
R K Ismail, and J van Breeschoten, and M W J M Wouters, and M van Dartel, and S van der Flier, and A K L Reyners, and P de Graeff, and A M G Pasmooij, and A de Boer, and K E Broekman, and D L Hilarius
Palbociclib and Letrozole in Advanced Breast Cancer.
November 2016, The New England journal of medicine,
R K Ismail, and J van Breeschoten, and M W J M Wouters, and M van Dartel, and S van der Flier, and A K L Reyners, and P de Graeff, and A M G Pasmooij, and A de Boer, and K E Broekman, and D L Hilarius
Palbociclib Prolongs Progression-Free Survival in Patients with Advanced Breast Cancer.
August 2015, American health & drug benefits,
R K Ismail, and J van Breeschoten, and M W J M Wouters, and M van Dartel, and S van der Flier, and A K L Reyners, and P de Graeff, and A M G Pasmooij, and A de Boer, and K E Broekman, and D L Hilarius
Tolerability of palbociclib in younger and older patients with advanced breast cancer.
January 2023, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,
R K Ismail, and J van Breeschoten, and M W J M Wouters, and M van Dartel, and S van der Flier, and A K L Reyners, and P de Graeff, and A M G Pasmooij, and A de Boer, and K E Broekman, and D L Hilarius
Updates on managing advanced breast cancer with palbociclib combination therapy.
January 2018, Therapeutic advances in medical oncology,
R K Ismail, and J van Breeschoten, and M W J M Wouters, and M van Dartel, and S van der Flier, and A K L Reyners, and P de Graeff, and A M G Pasmooij, and A de Boer, and K E Broekman, and D L Hilarius
Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review.
May 2024, Targeted oncology,
R K Ismail, and J van Breeschoten, and M W J M Wouters, and M van Dartel, and S van der Flier, and A K L Reyners, and P de Graeff, and A M G Pasmooij, and A de Boer, and K E Broekman, and D L Hilarius
Palbociclib Extends Survival in Advanced Breast Cancer.
July 2015, Cancer discovery,
Copied contents to your clipboard!